ATE204335T1 - Verfahren zur identifikation von mit hiv infizierten personen und zur überwachung ihrer therapie - Google Patents

Verfahren zur identifikation von mit hiv infizierten personen und zur überwachung ihrer therapie

Info

Publication number
ATE204335T1
ATE204335T1 AT93921375T AT93921375T ATE204335T1 AT E204335 T1 ATE204335 T1 AT E204335T1 AT 93921375 T AT93921375 T AT 93921375T AT 93921375 T AT93921375 T AT 93921375T AT E204335 T1 ATE204335 T1 AT E204335T1
Authority
AT
Austria
Prior art keywords
hiv
therapy
monitoring
identifying persons
persons infected
Prior art date
Application number
AT93921375T
Other languages
English (en)
Inventor
Fred I Chasalow
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Application granted granted Critical
Publication of ATE204335T1 publication Critical patent/ATE204335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93921375T 1992-09-08 1993-09-07 Verfahren zur identifikation von mit hiv infizierten personen und zur überwachung ihrer therapie ATE204335T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94092792A 1992-09-08 1992-09-08
US08/065,062 US5464740A (en) 1992-09-08 1993-05-20 Diagnositc agent and methods for identifying HIV infected individuals and monitoring their therapy
PCT/US1993/008370 WO1994005814A1 (en) 1992-09-08 1993-09-07 Diagnostic agent and methods for identifying hiv infected individuals and monitoring their therapy

Publications (1)

Publication Number Publication Date
ATE204335T1 true ATE204335T1 (de) 2001-09-15

Family

ID=26745162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921375T ATE204335T1 (de) 1992-09-08 1993-09-07 Verfahren zur identifikation von mit hiv infizierten personen und zur überwachung ihrer therapie

Country Status (12)

Country Link
US (2) US5464740A (de)
EP (1) EP0674718B1 (de)
KR (1) KR950703658A (de)
AT (1) ATE204335T1 (de)
AU (1) AU678990B2 (de)
BR (1) BR9307176A (de)
CA (1) CA2143872A1 (de)
DE (1) DE69330611T2 (de)
DK (1) DK0674718T3 (de)
ES (1) ES2163411T3 (de)
HU (1) HUT74412A (de)
WO (1) WO1994005814A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780222A (en) * 1995-04-10 1998-07-14 Alpha Therapeutic Corporation Method of PCR testing of pooled blood samples
US8615409B1 (en) 2005-04-15 2013-12-24 Recovery Data-Connect, L.L.C. System and method for identification, perfection, collection, and valuation of third-party claims including subrogation claims
ES2644334T3 (es) 2014-04-04 2017-11-28 Idcgs Clinica De Diagnosticos Medicos Biomarcadores para evaluar el VIH
CN110988178A (zh) * 2019-12-12 2020-04-10 谱尼测试集团股份有限公司 一种磷酸胆碱的高效液相色谱检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
US5122371A (en) * 1986-12-09 1992-06-16 Chaslow Fred I Biologically active agent having antihypertensive activity in mammals
US5028438A (en) * 1986-12-09 1991-07-02 Long Island Jewish Medical Center Biologically active agent having anti-hypertensive activity in mammals
CA2004410A1 (en) * 1988-12-02 1990-06-02 Fred I. Chasalow Diagnostic assay for breast cancer in human female patients

Also Published As

Publication number Publication date
ES2163411T3 (es) 2002-02-01
HU9500695D0 (en) 1995-04-28
WO1994005814A1 (en) 1994-03-17
EP0674718B1 (de) 2001-08-16
BR9307176A (pt) 1999-05-11
US5464740A (en) 1995-11-07
AU678990B2 (en) 1997-06-19
AU4848993A (en) 1994-03-29
CA2143872A1 (en) 1994-03-17
KR950703658A (ko) 1995-09-20
DE69330611T2 (de) 2001-11-29
EP0674718A4 (de) 1999-04-14
EP0674718A1 (de) 1995-10-04
DE69330611D1 (de) 2001-09-20
DK0674718T3 (da) 2001-12-10
US5643716A (en) 1997-07-01
HUT74412A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
DE3679708D1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
DE68909345D1 (de) Verfahren und Kompositionen zur Erzeugung verstärkter Chemilumineszenz von 1,2-Dioxetanen.
SE8206168D0 (sv) Preparations and process for preparation thereof
ES2115679T3 (es) Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados.
DE3788762D1 (de) Verfahren zur Bestimmung von physiologisch wirksamen Substanzen.
DE3773963D1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
AU5948090A (en) Silver enhanced gold-labelled immuno assay method
DE69005959D1 (de) Verfahren zur Reinigung von menschlichem Serum-Albumin.
AU2314088A (en) Method for rapid and sensitive detection of igm retroviral antibodies
FI893724A7 (fi) Hybridiproteiini C:n rakenteet ja menetelmät niiden valmistamiseksi
DE3783966D1 (de) Reagens zur pruefung von periodentalen erkrankungen.
ES2032529T3 (es) Una emulsion de agua y aceite termo-esterilizable.
DE3650147D1 (de) Verfahren zur bestimmung menschlicher lungenoberflächenaktiver substanz und reagenziensatz dazu.
DE3776525D1 (de) Immunochemisches verfahren zur bestimmung von stabilem glykosiliertem haemoglobin.
DE3889279D1 (de) Diagnostisches Mittel und Verfahren zur Bestimmung von Apolipoprotein B.
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
ATE204335T1 (de) Verfahren zur identifikation von mit hiv infizierten personen und zur überwachung ihrer therapie
DE3787706D1 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
Stevens et al. Immunochemical and electrophoretic properties of oestrous rabbit uterine fluid proteins obtained by uterine ligation
EP0293827A3 (de) Probe für Leishmaniosis
FI881355A7 (fi) Määritysmenetelmä hepatiittiantigeenien ja AIDS-vasta-aineiden toteamiseksi.
DE3583137D1 (de) Verfahren zur quantitativen bestimmung von bestandteilen von verbrennungsabgasen sowie einrichtung zur durchfuehrung des verfahrens.
ATE80226T1 (de) Verfahren zum nachweis von einer infektion oder entzuendung des harnbezueglichen tractus.
Boufassa et al. HEMOCO: a French prospective study of hemophiliacs infected by human immunodeficiency virus type 1 (HIV-1)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties